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Objectives: To determine whether valganciclovir 450 mg every 48 h for cytomegalovirus (CMV)
prophylaxis provides appropriate ganciclovir exposure in solid organ transplant recipients during
continuous renal replacement therapy (CRRT).
Patients and methods: Ganciclovir pharmacokinetics was intensively studied in two lung transplant
recipients under valganciclovir 450 mg every 48 h over one dosing interval. In vitro experiments using
blank whole blood spiked with ganciclovir further investigated exchanges between plasma and eryth-
rocytes.
Results: Ganciclovir disposition was characterized by apparent total body clearance of 3.3 and 5.8 L/h,
terminal half-life of 16.9 and 14.1 h, and apparent volume of distribution of 60.3 and 104.9 L in Patients
1 and 2, respectively. The observed sieving coefficient was 1.05 and 0.96, and the haemofiltration clear-
ance was 3.3 and 3.1 L/h. In vitro experiments confirmed rapid efflux of ganciclovir from red blood
cells into plasma, increasing the apparent efficacy of haemofiltration.
Conclusions: A valganciclovir dosage of 450 mg every 48 h appears adequate for patients under CRRT
requiring prophylaxis for CMV infection, providing concentration levels in the range reported for
900 mg once daily dosing outside renal failure.
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Introduction
Valganciclovir is currently supplanting oral ganciclovir in
various indications, such as the prophylaxis of cytomegalovirus
(CMV) infection in solid organ transplant patients. The prodrug,
valganciclovir, is characterized by better oral bioavailability.
After administration, valganciclovir is hydrolysed to ganciclovir
and extensively eliminated by the kidney, through both glomeru-
lar filtration and tubular secretion. Thus, in renal insufficiency,
the dosage of valganciclovir has to be adjusted to the estimated
glomerular filtration rate (GFR).1 The manufacturer suggests a
scheme for dosage adaptation as a function of GFR, but does
not recommend the use of valganciclovir in patients requiring
intermittent dialysis or continuous renal replacement therapy
(CRRT). The high clearance of ganciclovir in healthy subjects
(14 L/h)1 indicates that tubular secretion contributes to a
similar extent as glomerular filtration (7 L/h). CRRT replaces
only GFR and usually does not exceed half of a normal GFR.
Thus, a rational dosage adjustment in CRRT patients would not
exceed a quarter of the usual dose intensity, for example 450 mg
every second day instead of 900 mg once daily. We aimed to
confirm in two patients receiving CRRT through continuous
veno-venous haemofiltration (CVVHF) that this dosing schedule
provides adequate ganciclovir exposure in such a condition.
Patients and methods
This observational study was performed at the Lausanne University
Hospital, Switzerland, with the approval of the local Ethics
Committee, in two lung transplant recipients at risk for CMV
infection.
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Patient 1
A 49-year-old, 92 kg male patient was admitted for double lung
transplantation in the context of idiopathic pulmonary fibrosis.
Valganciclovir prophylaxis was started on day 1 post-transplantation
(900 mg once daily initially). On day 3, his condition deteriorated
with cardiogenic and subsequent septic shock and multi-organ
failure requiring initiation of CRRT. The CVVHF apparatus
(Aquarius, Edwards Lifesciences S.A., St-Prex, Switzerland) was
equipped with a 0.12 m2 polyethersulfone fibre filter (Aquamax
HF12, Edwards Lifesciences S.A.) connected through a double
lumen venous catheter. On day 14, the treatment conditions were set
to 300 mL/min blood flow, 3 L/h post-dilution flow (lactate-buffer
electrolyte-glucose solution) and 150 mL/h patient’s volume sub-
traction. The patient was anuric. He received his last valganciclovir
900 mg dose 48 h before switching to 450 mg dose every second
day on the day of observation. Valganciclovir was given through a
nasogastric tube after dissolution of the tablet in warm water.
Concomitant drug therapy consisted of norepinephrine, midazolam,
fentanyl, sufentanil, heparin, mycophenolate, tacrolimus, methyl-
prednisolone, vancomycin, voriconazole, tazobactam/piperacillin,
insulin, esomeprazole and neostigmine. CRRT was followed by
intermittent chronic haemodialysis. The patient died 4 months later
from septic shock.
Patient 2
A 54-year-old, 46 kg Asian male patient was admitted for a second
double lung transplantation because of bronchiolitis obliterans,
Mycobacterium, Pseudomonas and Aspergillus infections of the first
allograft. During the intervention, haemorrhagic shock led to acute
renal failure and the initiation of CRRT (same supplies as Patient 1).
Valganciclovir prophylaxis was started on day 8 post-transplantation
(450 mg every 48 h; the valganciclovir tablet being crushed and dis-
solved in cold water before administration through nasogastric tube).
On day 19, the CVVHF conditions were set to 250 mL/min blood
flow, 1 L/h pre-dilution flow, 3 L/h post-dilution flow and 180 mL/h
patient’s volume subtraction. The patient was anuric. Concomitant
drug therapy consisted of norepinephrine, propafenone, sufentanil,
propofol, lorazepam, heparin, mycophenolate, cyclosporine, methyl-
prednisolone, vancomycin, tazobactam/piperacillin, ethambutol,
azithromycin, caspofungin, lamivudine, colistimethane, nystatin,
insulin and esomeprazole. He died 2 months later from cardiac
arrest.
Sample collection and assay
Blood samples were collected from both arterial and venous lines,
along with filtrate samples from the output line, at 0 (before drug
administration), 1, 2, 3, 4, 6, 12, 24, 36 and 48 h after administration
of valganciclovir 450 mg. Blood samples were centrifuged, and
plasma and filtrate samples stored at –208C until analysis.
Ganciclovir concentration in plasma was measured using a vali-
dated high-performance liquid chromatography method after protein
precipitation, on a reversed-phase C18 column, using a mobile-
phase gradient of sodium heptanosulfonate 0.4% buffer (pH 2.6)
and acetonitrile, and spectrofluorimetric detection.2 The lower limit
of detection was 0.1 mg/L, the inter-day coefficient of variation was
,3.5% and the range of inter-day deviations was comprised within
20.4% to 21.4%. Filtrate samples were analysed using calibration
and quality controls prepared with blank filtrate.
In vitro experiments
A spiking experiment was performed after examination of study
results to investigate the importance and kinetics of ganciclovir
exchanges between plasma and erythrocytes. Ganciclovir per-
meation across the red blood cell membrane was assessed at 378C in
two phases: influx and efflux study. A citrated blood sample from a
healthy donor was spiked with ganciclovir dissolved in 0.9% NaCl
to yield a concentration of 5 mg/L. For the influx study, 4 mL ali-
quots were drawn at 0, 5, 10, 20, 30, 45 min, 1, 1.5, 2, 2.5, 3 and
4 h and centrifuged at 1850 g for 4 min at þ48C. Plasma and blood
cells were separately stored frozen at 2208C prior to analysis. After
the 4 h of incubation period, the remaining plasma was separated by
centrifugation, removed and replaced by a volume of blank plasma
of the same donor adjusted to reach the same haematocrit. In the
subsequent efflux study, samples were drawn at 0, 5, 10, 20, 30,
45 min, 1, 1.5 and 2 h and processed as described earlier. To
exclude the occurrence of degradation, ganciclovir concentrations
were measured in one control blood sample spiked with ganciclovir
at 5 mg/L, left in parallel for 6 h at 378C. For ganciclovir determi-
nation in erythrocytes, haemolysed samples were analysed using
matrix-matched calibration and quality control prepared with hae-
molysed red blood cells.
Pharmacokinetic analysis
Ganciclovir concentration–time data in plasma and filtrate were ana-
lysed using non-compartmental methods. The area under the curve
during one dosing interval (AUC0–48) was estimated by trapezoidal
and log-trapezoidal methods, and the apparent total body clearance
(CLTOT/F) was calculated as the dose divided by AUC0–48. This
analysis was completed by curve fitting with a two-exponential
model, enabling the estimation of an initial (l1) and a terminal rate
constant (lZ). The elimination half-life (t1/2) was derived as
loge(2)/lZ and the apparent terminal volume of distribution (VZ/F)
as CLTOT/lZ. Two approaches were used to determine the clearance
of ganciclovir through the CRRT apparatus. The first is based on the
amount of drug removed from blood, calculated from ganciclovir
plasma pre-filter (CA) and post-filter (CV) concentrations and
defined as ‘haemofiltration clearance’ (CLCRRT). The second com-
pares simultaneous filtrate and ‘arterial’ plasma concentration. Their
ratio is taken as sieving coefficient (SC) and the filtration clearance
(CLF) is estimated by the product of SC and total filtrate flow,
reflecting the rate of drug appearance in the filtration fluid, divided
by the circulating concentration. The recovery (R) in the filtrate is
calculated as the ratio of CLCRRT over CLF. SC, CLCRRT and CLF
are calculated for each sampling time and averaged using the
geometric mean.3
Results and discussion
The concentration–time profiles of ganciclovir in Patients 1 and
2 receiving valganciclovir 450 mg every 48 h are shown in
Figure 1 and the resulting pharmacokinetic parameters are given
in Table 1. For Patient 2, samples were collected over 24 h
instead of 48 h because CRRT was interrupted after 24 h due to
filter failure. Cmax, Cmin and AUC0–48 determined for Patient 1
may be influenced by his prolonged dosage of 900 mg once a
day, with a change to 900 mg every second day, two days before
investigation. This may have affected AUC0–48 and CLTOT/F
but not CLCRRT, SC and CLF.
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Valganciclovir has proved successful for the prophylaxis
of CMV in solid organ transplant recipients without renal
impairment at 900 mg once daily.4 The AUC calculated for
Patient 2 is in the range reported with 900 mg once daily
(42–63 mg.h/L)4–7 and Patient 1 shows an even higher
exposure. CLTOT/F obtained in both patients is much lower
than CLTOT/F reported in the absence of renal impairment
(10.2–15.5 L/h)4–7 and corresponds to values reported for
patients with fairly reduced GFR.1 Accordingly, t1/2 is longer
than in patients without renal impairment (5 h in liver recipi-
ents5 and 3.5 h in healthy subjects1) and is in the range reported
for patients under CRRT receiving intravenous ganciclovir.8–10
Vz/F determined in these two patients are in the range reported
for healthy subjects and patients with and without renal impair-
ment.1 These results are in accordance with the almost exclusive
renal elimination of ganciclovir, including a large component of
tubular secretion, which is not replaced by CRRT. In addition,
the dose preparation and nasogastric tube administration seem
not to grossly impair drug absorption.
In Patient 1, CLCRRT based on plasma disappearance rate and
CLF estimated from appearance in filtrate-dialysate accounted
for 70% to 100% of the apparent total clearance. Accordingly,
the average recovery of ganciclovir was 104% and the sieving
coefficient was 1.05. In Patient 2, CLCRRT and CLF accounted
for 50% to 60% of the apparent total clearance and indicated
the average recovery of 87% and the sieving coefficient of 0.96.
These results are in accordance with sieving coefficients and
percentage of total clearance achieved by CRRT previously
reported for ganciclovir (0.75 to 0.95 and 40% to 115%,
respectively).8–10
The profile (concentration versus time) of ganciclovir influx
and efflux through red blood cell membranes is shown in
Figure 2. In the first phase (influx study), ganciclovir enters
erythrocytes to reach an equilibrium between cells and plasma
(erythrocytes/plasma ratio ¼ 0.77). In the second phase (efflux
study), ganciclovir leaves the erythrocytes following the concen-
tration gradient between cells and plasma for attaining the same
ratio. Of note, ganciclovir concentrations in plasma and red
Figure 1. Concentration–time points and fitted bi-exponential curves of
ganciclovir in ‘arterial’ and ‘venous’ lines and in filtrate in Patients 1 (lower
panel) and 2 (upper panel) (filled circles and solid black line: ‘arterial’
concentrations; open circles and dotted black line: ‘venous’ concentrations;
triangles and solid grey line: filtrate concentrations).

























1 450a 6.5 0.7 98.0 0.62 0.041 16.9 3.3 80.7 2.4 1.05 3.3 104
2 450a 3.1 0.2b 55.4 0.65 0.049 14.1 5.8 118.6 3.5 0.96 3.1 87
aCorresponding to 324.1 mg of ganciclovir.
bValue extrapolated from lZ.
Figure 2. Concentration–time points and fitted exponential curves obtained
from the in vitro ganciclovir permeation experiment. A 90 mL citrated blood
volume obtained from a healthy donor was spiked with an amount of 500 mg
ganciclovir (dissolved in 10 mL 0.9% NaCl) on time 0. During 4 h (‘influx’
phase), the blood pool was regularly sampled and ganciclovir concentration
was followed up in the plasma (open circles and grey line) and in the red
blood cells (filled circles and black line). On time 4 h, all the remaining
plasma was separated by centrifugation and replaced with an identical
volume of blank plasma from the same donor. Ganciclovir concentration was
again followed up in the plasma and in the erythrocytes during the next 2 h
(‘efflux’ phase). The profile was fitted according to a two-compartmental
model with passive bidirectional diffusion (see text).
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blood cell control samples remained stable for 4 and 6 h at 378C
and without any change of pH. Ganciclovir was previously
reported to enter erythrocytes through nucleobase and nucleoside
transporters.11 In our experiment, we show that ganciclovir also
leaves red blood cells in accordance with the concentration gra-
dient. This phenomenon could play a role during blood filtration
by CRRT as the plasma/erythrocytes equilibrium is modified
while ganciclovir is removed from plasma. Such exchanges
occur in the haemofiltration filter and during post-dilution,
providing an explanation for sieving coefficients and recovery
fraction greater than the unity, as observed in Patient 1. Thus,
drug transport by red blood cells may increase CRRT efficacy
for substances with significant distribution in the erythrocytes, a
compartment often neglected in pharmacokinetics.12
In conclusion, a 450 mg valganciclovir dose administered
every 48 h achieves, in transplant recipients under CRRT,
exposure levels similar to those observed under the usual dosage
(900 mg once daily) recommended in the absence of renal failure.
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